This is the latest version of this eprint.
Li, J, Fairhurst, C, Peckham, E et al. (8 more authors) (2020) Cost‐effectiveness of a specialist smoking cessation package compared with standard smoking cessation services for people with severe mental illness in England: a trial‐based economic evaluation from the SCIMITAR+ study. Addiction, 115 (11). pp. 2113-2122. ISSN 0965-2140
Abstract
Aims:
To evaluate the cost‐effectiveness of a specialist smoking cessation package for people with severe mental illness
Design:
Incremental cost‐effectiveness analysis was undertaken from the UK National Health Service and Personal Social Services perspective over a 12‐month time horizon. Total costs, including smoking cessation, health‐care and social services costs and quality‐adjusted life years (QALYs), derived from the five‐level EuroQol 5‐dimension (EQ‐5D‐5 L), collected from a randomized controlled trial, were used as outcome measures. The bootstrap technique was employed to assess the uncertainty.
Setting:
Sixteen primary care and 21 secondary care mental health sites in England.
Participants:
Adult smokers with bipolar affective disorder, schizoaffective disorder or schizophrenia and related illnesses (n = 526).
Intervention and comparator:
A bespoke smoking cessation (BSC) package for people with severe mental illness offered up to 12 individual sessions with a mental health smoking cessation practitioner versus usual care (UC). Of the participants who were randomized, 261 were in UC group and 265 were in BSC group.
Measurements:
BSC intervention cost was estimated from the treatment log. Costs of UC, health‐care and social services and EQ‐5D‐5 L were collected at baseline, 6‐ and 12‐month follow‐ups. Incremental costs and incremental QLAYs were estimated using regression adjusting for respective baseline values and other baseline covariates.
Findings:
The mean total cost in the BSC group was £270 [95% confidence interval (CI) = –£1690 to £1424] lower than in the UC group, while the mean QALYs were 0.013 (95% CI = –0.008 to 0.045) higher, leading to BSC dominating UC (76% probability of cost‐effective at £20 000/QALY).
Conclusions:
A bespoke smoking cessation package for people with severe mental illness is likely to be cost‐effective over 12 months compared with usual care provided by the UK's National Health Service and personal social services.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/) |
Keywords: | Cost‐effectiveness; cost–utility; economic evaluation; severe mental illness; smoking cessation; tobacco use |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Healthcare (Leeds) > Nursing Mental Health (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 12 Oct 2020 12:33 |
Last Modified: | 07 Nov 2024 15:26 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1111/add.15086 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:166489 |
Available Versions of this Item
-
Cost-Effectiveness of a Specialist Smoking Cessation Package Compared with Standard Smoking Cessation Service for People with Severe Mental Illness in England: A Trial-Based Economic Evaluation From the SCIMITAR+ Study. (deposited 07 Nov 2024 15:22)
- Cost‐effectiveness of a specialist smoking cessation package compared with standard smoking cessation services for people with severe mental illness in England: a trial‐based economic evaluation from the SCIMITAR+ study. (deposited 12 Oct 2020 12:33) [Currently Displayed]